Roth Capital Downgrades Pharmacyclics (PCYC) to Neutral
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 6
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 6
Join SI Premium – FREE
Roth Capital downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral with a price target of $57.00.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $62.89 yesterday.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $62.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Man Group Plc. (EMG:LN) (MNGPY) to Neutral
- Baird Downgrades Medpace (MEDP) to Neutral
- BNP Paribas Exane Downgrades Acerinox SA (ACX:SM) (ANIOY) to Underperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
